Skip to content

General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening

Effect of Eligible Patients Paper-based Reminder for General Practitioners on Colorectal Cancer Screening Participation

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01364454
Enrollment
8140
Registered
2011-06-02
Start date
2010-06-30
Completion date
2011-06-30
Last updated
2016-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal Cancer Screening, Faecal Occult Blood test, General Practitioners Involvement, Patient's Participation, Reminder

Brief summary

Screening for ColoRectal Cancer (CRC) is widely recommended because of compelling evidence that it reduces mortality from CRC and that it's cost-effective. In France, there is a national CRC screening programme inviting people aged 50-74 years by mail to consult their General Practitioner (GP) for a free on charge Faecal Occult Blood test deliverance every two years. Participation is a key factor for the screening programs success. High levels of screening uptake and the continued participation to regular screening must be achieved and maintained in the targeted population if the enormous potential of CRC screening is to be realised. Screening rates of various international programs vary widely (20-52%) and the participation is insufficient in the most settings. Therefore, a better understanding of facilitating and hindering factors of patient participation can guide interventions to improve CRC screening rates. They include patients and physicians' factors. One issue is about GPs practice. GP involvement has been shown to improve the participation in the CRC screening. This study aims to assess the effectiveness of an intervention targeting GPs to increase patient participation in the CRC screening. Volunteer GPs will be randomly assigned to either the intervention group or to usual care (control group) and they will be followed one year. The intervention consists in providing every four months to the experimental group a list of their patients who are eligible but did not proceed yet to the screening. In both groups, patient participation in the screening will be measured at the end of the study.

Interventions

OTHEREligible patients' paper-based reminder

Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason

Sponsors

Paris 12 Val de Marne University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

1. General Practitioner (GP) * exercising in the Val de Marne (French department of the suburb of Paris) * volunteered to participate at the study 2. Patient * living in the Val de Marne (French department of the suburb of Paris) * having declared a 'preferred GP' exercising in the Val de Marne to the main statutory health insurance scheme (régime général) * being eligible for colorectal cancer screening (aged 50 to 74 years, not excluded and having not proceed yet to the screening) * having consulted his 'preferred GP', whatever the reason, during the study period

Design outcomes

Primary

MeasureTime frameDescription
Patient's participation to colorectal cancer screening program1 yearPatient's status with colorectal cancer screening program to 15th june 2011 with two modalities 1. Update: completion of Faecal Occult Blood test or exclusion for medical reason within the duration of the study (The medical exclusions of the program are a personal or family history of Colorectal cancer, Crohn's disease, hemorrhagic rectocolitis, or hereditary nonpolyposis colorectal cancer, a colonoscopy undergone in the 5 previous years or a Fecal Occult Blood test undergone in the 2 previous years) 2. Not update

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026